The DOI matches its Crossref record; 228 of the 229 references it cites were found in a registry or an index.
Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease
Open accessAbstract
Drosophila melanogaster is a valuable model organism for a wide range of biological exploration. The well-known advantages of D. melanogaster include its relatively simple biology, the ease with which it is genetically modified, the relatively low financial and time costs associated with their short gestation and life cycles, and the large number of offspring they produce per generation. D. melanogaster has facilitated the discovery of many significant insights into the pathology of Parkinson’s disease (PD) and has served as an excellent preclinical model of PD-related therapeutic discovery. In this review, we provide an overview of the major D. melanogaster models of PD, each of which provide unique insights into PD-relevant pathology and therapeutic targets. These models are discussed in the context of their past, current, and future potential use for studying the utility of secondary metabolites as therapeutic agents in PD. Over the last decade, senolytics have garnered an exponential interest in their ability to mitigate a broad spectrum of diseases, including PD. Therefore, an emphasis is placed on the senolytic and senomorphic properties of secondary metabolites. It is expected that D. melanogaster will continue to be critical in the effort to understand and improve treatment of PD, including their involvement in translational studies focused on secondary metabolites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, senolytic and senomorphic secondary metabolites inhibit α-syn aggregation and prolong the healthspan in PD models.431”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [431]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Ahmad, A., Ali, T., Park, H. Y., Badshah, H., Rehman, S. U., & Kim, M. O. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9795-4 · Cited by 216
RetractedYang, D., Li, T., Liu, Z., Arbez, N., Yan, J., Moran, T. H., Ross, C. A., & Smith, W. W. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.020 · Cited by 64
RetractedResveratrol attenuates inflammation environment-induced nucleus pulposus cell senescence in vitro
Li, X., Lin, F.-X., Wu, Y., Liu, N., Wang, J., Chen, R., & Lu, Z. (2019) · Bioscience Reports · doi:10.1042/bsr20190126 · Cited by 60
RetractedMitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release
Zorov, D. B., Juhaszova, M., & Sollott, S. J. (2014) · Physiological Reviews · doi:10.1152/physrev.00026.2013 · Cited by 5,383
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Sirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
NRF2, a Transcription Factor for Stress Response and Beyond
He, F., Ru, X., & Wen, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134777 · Cited by 1,820 · cited 1×
“Similarly, the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is a critical regulator of the cellular response to oxidative stress (59).”
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 8×
“Moreover, PRKN overexpression in D. melanogaster can rescue mitochondrial defects caused by other genetic mutations or environmental stressors (35).”
InfluentialMitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 1×
“…seminal study and other early work revealed that a loss of the D. melanogaster PINK1 homolog (CG4523) results in fragmented mitochondria, reduced ATP levels, muscle degeneration, locomotor deficits, dopaminergic neuronal loss, male sterility, and increased sensitivity to oxidative stress (27, 28).”
The Drosophila melanogaster Genetic Reference Panel
Mackay, T. F. C., Richards, S., Stone, E. A., Barbadilla, A., Ayroles, J. F., Zhu, D., Casillas, S., Han, Y., Magwire, M. M., Cridland, J. M., et al. (2012) · Nature · doi:10.1038/nature10811 · Cited by 1,656
Research works printed but not linked: 2
- de la Rosa, 2018, Phenolic compounds
- Jhonsa, 2016, Neuroprotective effect of flavonoids against paraquat induced oxidative stress and neurotoxicity in Drosophila melanogaster, Curr Topics Nutraceutical Res, 14, 283
Cited by
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
SIRT1 Activators as Geroprotective Agents in Brain Aging: Mechanisms and Therapeutic Potential
Alameen, A. A. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Faheem, S. A., & Batiha, G. E. (2026) · NeuroMolecular Medicine · doi:10.1007/s12017-026-08923-y · Cited by 12
Kell, D. B., Kell, L., Kenny, L. C., Merriel, A., Moore, J. B., & Pretorius, E. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104621 · Cited by 10
Atere, T. G., WAHYUNI, D. K., Avwioroko, O. J., Bayo-Olugbami, A. A., IDOWU, O. K., Arogundade, M. T., FAKOLUJO, E. I., DARAMOLA, O., OYAYEYE, O. D., & Aderemi, A. V. (2025) · Notulae Scientia Biologicae · doi:10.55779/nsb17112341 · Cited by 6
Senolytics and cell senescence: historical and evolutionary perspectives
Finch, C. E. (2024) · Evolution Medicine and Public Health · doi:10.1093/emph/eoae007 · Cited by 6
Metadata
- Authors
- Miller, S. J., Darji, R. Y., Walaieh, S., Lewis, J. A., & Logan, R.
- Affiliations
- Yale University (US)
- Eastern Nazarene College (US)
- Corresponding author
- Logan, Robert
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2023-09-28
- Volume
- 14
- Pages
- 1271941-1271941
- ISSN
- 1664-2295 (ISSN-L)
- PMC
- PMC10568035
- OpenAlex
- W4387133284
- Cited by
- 16
- References
- 229
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 2
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, senolytics, secondary metabolites, Drosophila model, Parkinson's disease model, neurodegeneration, therapeutic agents, translational research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease. https://app.cochat.ai/papers/10.3389/fneur.2023.1271941
- The paper
- Miller, S. J., Darji, R. Y., Walaieh, S., Lewis, J. A., & Logan, R. (2023). Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease. Frontiers in Neurology. https://doi.org/10.3389/fneur.2023.1271941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.